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Prognostic Factors and Scores
in Post-Transplantation
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Solid Organ Transplantation
TO THE EDITOR:We have read with great interest the article by
Evens et al,1 in which they report amulticenter analysis of 80 patients
with post-transplantation lymphoproliferative disorder (PTLD) after
solid organ transplantation. Based on a multivariate analysis, the au-
thors propose a new prognostic model, which clearly distinguishes
three groups with markedly different progression-free survival (PFS)
and overall survival (OS) rates. As external validation of prognostic
scores is important and inevitably ismainly based on other retrospec-
tive series in raredisorders suchasPTLD,weraise someconcernabout
the exact definition of prognostic factors.
Until now,most data regardingPTLDarederived retrospectively
from registry databases and single-center series. Whereas the main
strength of registries is comprised by the large numbers of patients,
smaller single or multicenter studies seem to provide more detailed
information on potential prognostic factors. In this way, the article by
Evens et al,1 which identifies hypoalbuminemia as a new strong prog-
nostic factor, adds important value to our current knowledge of
PTLD. Identification of prognostic factors in PTLD has been limited
by different reasons including mainly heterogeneity in patient popu-
lation, immunosuppressive therapy, disease itself, and treatment op-
tions. A number of prognostic scores have been proposed in different
transplantation populations, although none of them have been vali-
dated in other series.2-5
CNS involvement has been proposed as a poor prognostic factor
in PTLD.2,6 Evens et al1 were able to confirm this association in their
analysis and found that it maintained prognostic significance on PFS
and OS in multivariate analysis. However, all patients with CNS in-
volvement (13%) presented with primary CNS lymphoma, probably
implying that these patientswere all symptomatic at diagnosis.1 As the
authors did not mention the definition of CNS involvement in their
analysis, overt CNS involvement might have been present. External
validationof their prognostic score canonlybepossible if information
is givenon the definitionofCNS involvement, being either only based
on clinical symptoms or based on CSF examination and/or CNS
imaging. By searching our own single-center database, we identified
115 patients diagnosed with PTLD during the period from 1989 to
2009. Of these patients, six presented with CNS involvement (5.2%),
of whomfivewere considered to have primaryCNS lymphoma. In 35
patients (30.4%), CSF examination and/or CNS imaging were per-
formed, whereas in the majority (64.4%), neither of these were done
because of the absence of neurologic symptoms. If we were to try to
validate the prognostic scores of only those patients who underwent
specificCNS-directed investigations inEvenset al, 41patients (35.6%)
would be evaluable for this analysis, whereas if only symptomatic
patientswere consideredCNS-involvementpositive, all patients could
be evaluated for this risk factor.
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